



Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open  Access

Review Article

Inulin: A promising carrier for controlled and targeted drug delivery system

Akram Wasim*, Joshi Ramakant, Garud Navneet

School of studies in Pharmaceutical Sciences, Jiwaji University, Gwalior, M.P-474011

ABSTRACT

The delivery of a drug to the preferred site of action is referred to as drug targeting. The benefits of drug targeting are a reproducible and controlled release rate of the therapeutic compound, which forestalls overdose. Due to the potential to treat colonic diseases with minimum side effects, colon targeting has become of high interest over the last decades. Inulin was investigated for its potential as encapsulation material regarding its enzymatic degradability and its drug release behaviour. Inulin is a polysaccharide with a widespread range of therapeutic uses such as a carrier in a drug delivery vehicle, as a diagnostic/analytical tool or as a dietary fibre with additional health benefits. In the main, much research has focused on inulin as a drug delivery carrier for colon-specific drug delivery. The justification for this is its potential to survive in the stomach's acidic environment. This unique stability and strength are utilized in many ways to deliver drugs safely to the colon, where they can be easily absorbed through the gut epithelium into the blood. There are also some proofs that inulin's prebiotic features also lead to health benefits, mainly for patients with inflammatory bowel disease or in the prevention of colonic cancer. Inulin based hydrodynamic research will be useful to discover the potential of inulin.

Keywords: Drug targeting, Controlled release, Inulin, Prebiotic

Article Info: Received 24 Dec 2018; Review Completed 29 Jan 2019; Accepted 01 Feb 2019; Available online 15 Feb 2019



Cite this article as:

Akram W, Joshi R, Garud N, Inulin: A promising carrier for controlled and targeted drug delivery system, Journal of Drug Delivery and Therapeutics. 2019; 9(1-s):437-441 <http://dx.doi.org/10.22270/jddt.v9i1-s.2398>

*Address for Correspondence:

Akram Wasim, School of studies in Pharmaceutical Sciences, Jiwaji University, Gwalior, M.P-474011

1. Introduction

The delivery of a drug to the desired site of action is referred to as drug targeting. The benefits of drug targeting are a reproducible and controlled release rate of the therapeutic compound, which forestalls overdose. Moreover, the unwanted effects and toxicity of drug are minimized¹. Now day's colon targeting has become of high interest, due to the potential to treat colon specific diseases with minimized side effects². For colon specific targeting, it is essential that the therapeutic formulation bypass the stomach and the small intestine in a non-degraded form³. Various bio-polymers like polysaccharides have been investigated as prospective encapsulation materials for therapeutic substances⁴. Inulin is a versatile plant-derivative carbohydrate with the benefits of soluble dietary fiber⁵. Inulin is not digested or absorbed in the stomach and in the small intestine but is fermented in the colon by advantageous bacteria. Inulin functioning as a prebiotic has been linked with enhancing the gastrointestinal system and the immune system. The natural polymer inulin has numerous applications in the food and pharmaceutical industry due to its exclusive chemical and physical properties^{6,7}. Inulin is non-toxic biopolymer and its $\beta(2-1)$ -glycosidic-linked fructosyl units are indigestible by the upper

gastrointestinal tract of humans⁸. However, inulin can be partly or totally metabolized by the colonic microbiota to acetate, propionate, lactic acid, hydrogen, and carbon dioxide⁹⁻¹¹. Consequently, inulin is used as a prebiotic food element with accredited positive effects on human health.

Stevens et al. reported that ingested inulin is not altered in monosaccharides by the digestive juices. Therefore, the glycemia and the level of insulin in the blood remain steady and the inulin reaches in the large intestine where it is fermented¹². This condition is caused by a specific bond, $\beta(2-1)$ linked fructose present in the molecule of inulin¹³, which confers that it cannot be processed by the human digestive system so the inulin passes through stomach, small intestine without degradation and stops in the large intestine where it produces a healthy microflora (Bifidobacterium). This shows that inulin is a natural prebiotic (an ingredient that belongs to the prebiotic family requires two stipulations: it should not be digested by the digestive enzyme, and it can only undergo fermentation in the colon. Various physiological effects implemented by inulin are summarized in Table 1.

Table 1: The physiological function of inulin in the large bowel ¹⁴

Large Bowel	Inulin Functionality
Attenuation of faecal pH	+
Production of short chain fatty acids	+
Promote growth of <i>Bifidobacteria</i>	+
Increase stool frequency	+
Decrease intestinal transit time	-
Increase stool weight	-
Improvement of stool consistency	+

Now a day's inulin is a promising molecule with researches and applications in medicine, pharmacology or food industry, because of its bioactivity ¹⁵. In medicine, inulin has manifold functions, such as: maintaining the microflora of the colon, improving metabolism, maintaining gastrointestinal health ¹⁶. A relative latest finding confirmed that pure inulin promoted *Collinsella* growth in the gastrointestinal tract. In addition, Smecuol et al. ¹⁷ found that inulin-type fructans contribute to the rise of *Bifidobacterium infantis* probiotic strains that have a positive effect on subjects with active coeliac disease, a chronic inflammation of the intestinal mucosa ensuing from an extreme immune response to dietary gluten in genetically predisposed individuals. The colonic disorder is quite hard to treat because orally administrated therapeutics are absorbed in the stomach and intestine levels and they do not reach the colon, while intravenous administrated therapeutics are eliminated from the body before reaching the colon. The fact inulin is not degraded or absorbed in the stomach or in the small intestine, but it is degraded by colonic bacteria, various inulin based pharmaceutical formulations have been developed that can be used as a promising carrier for targeting of drugs into the colon ^{13,18}.

2. Inulin

2.1 Origin and Identity

Rose discovered Inulin, a German scientist, in 1804 from the roots of *Inulahelenium* found "a peculiar substance" from plant origin, a genus of perennial herbs of the group *Composit~e*, inhabitants of the temperate regions of Europe, Asia, and Africa ¹⁹. The substance was named inulin but was also known by other names such as ashelenin, alantin, meniantin, dahlin, sinantemin and sinisterin. In the mid of the 19th century, the biochemical production was elucidated.

Inulin comes under a general class of fructose-containing polymers known as fructans. Fructans assist as storage polymers in numerous members of the *Composit~e* family such as *Cichoriumintybus* (chicory), *Inulahelenium* (elecampane), *Taraxacumofficinale* (dandelion) and *Helianthus tuberosus* (Jerusalem artichoke). Inulin pulls out from chicory is a natural polydisperse carbohydrate ²⁰. It is a fructan which mainly comprises linear chains of 1, 2-[3-linked d-fructofuranose units bound by an (od-132) type linkage (as in sucrose) to a terminal glucose moiety. The fructans that are found in the dicotyledons, and in some monocotyledons, are of this type. By assessment, fructans primarily composed of linear fructose units bound by a [3-(2---~6) glycosidic bond. The gross molecular formula of inulin is GF with G being a terminal glucosyl unit, F shows

the fructosyl units and n demonstrating the number of fructosyl units [Fig. 1] ²¹.




Figure 1: Basic structure of Inulin

2.2 Source and preparation

Inulin occurs in thousands of plant species, including asparagus, banana, garlic, and onion. The chicory (*Cichorium intybus*) root is the main commercial source where inulin constitutes 16% to 18% of the dry matter. Some inulin is also obtained from tubers of Jerusalem artichoke (*Helianthus tuberosus* L.). Inulin has been taken by humans since ancient times. Before the potato was introduced into Western Europe in the latter half of the 16th century, the Jerusalem artichoke tuber (14%-19% inulin) was a main source of carbohydrate. Chicory roots (and Jerusalem artichoke tubers) must be processed soon after harvesting (possibly on the same day, but not more than 7 days after harvesting) because they deteriorate quickly. The harvested roots are washed, sliced, and extracted with hot water. Colloidal materials, colored substances, and other solubles (salts, amino acids, sugars, etc.) are isolated from the extract by a purification/clarification process involving treatment with calcium hydroxide (lime) to precipitate protein, followed by treatment with CO₂ to counteract the alkaline mixture and to precipitate any calcium ions in solution as calcium carbonate, centrifugation, filtration through an adsorbent and/or activated carbon, and ion exchange, a process analogous to that used in purifying sucrose extracts. The extract is then concentrated by evaporation and spray-dried followed by ultrafiltration. The inulin may also be recovered by crystallization or precipitation. Even with extensive care, inulin extracted from chicory roots is still mainly a mixture of oligosaccharides. The commercial preparation contains 2% monosaccharides, 5% disaccharides, and 93% molecules of DP 3-60, with an average DP of 8-10. The maximum average DP of chicory root inulin is about 15, representing a comparatively high percentage of molecules of low DP. The maximum amount of inulin in chicory roots is about 18% (dry basis). ²²

3. Controlled and targeted drug release by Inulin complexes

Inulin offers controlled release of therapeutics to the colon because it provides protection against the acidic environment in the stomach for the encapsulated drug as well as allowing degradation in the colon in the presence of the colonic microbiota ²³. The potential of inulin, as a coating system, with its effectiveness in controlled drug release was tested by ²⁴ swelling tests, water vapour transmission tests and drug permeability in colonic media was evaluated using

polymethacrylates (eudragit) with and without inulin. In the absence of inulin polymers, drug release was controlled by the pH of the media. The swelling behaviour and permeation of drug were observed more with inulin dependent system as compared to the pH-dependent polymers (24). Drugs with low water solubility have low bioavailability due to partial solubility and thus present a dilemma in successful drug delivery²⁵. Irbesartan tablet was prepared by mixing it with inulin and poly (acrylic acid) grafted inulin. The flower-like platelets of inulin, surrounding the drug were observed that consequently increased the drug dissolution. Increasing inulin concentration increased the drug solubility²⁶. Quality of inulin to form aggregates in different solutions like water, DMSO and CnTAB (cetyl trimethylammonium bromides) and CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate) can be useful for the solubilisation and encapsulation of drugs²⁷. The physicochemical interaction with cationic amphiphilic surfactants CnTAB of varied alkyl chain length was studied at a variable concentration of CnTAB and inulin. Increasing concentration of alkyl group was reported to strengthen the inulin aggregates up to a moderate concentration of the amphiphile. At very high concentrations the amphiphile formed free micelles²⁸. Inulin incorporation in a three-layer coating system has also been reported by Ravi et al. A tablet made up of the drug Diltiazem HCl matrixed with chitosan and guar gum was used. This tablet was bounded by inulin (inner) and shellac (outer) layer. The outer and inner coats were intended to provide protection against gastric and intestinal environments, respectively. The drug was then released in the colon with the degradation of the other two polysaccharides^{29,30}.

Due to its resistance to the gastric fluid and degradation in the distal intestine inulin was used as a promising carrier to deliver butyrate to its site of action. The study was conducted in order to recognize the apoptotic potential against colonic cancerous cells and showed that the use of inulin provided secure targeting of butyrate to its site of action³¹.

3.1 Hydrogels of Inulin

A range of inulin hydrogels has been developed to be used as potential carriers for the targeting of drugs with variable composition into the colon³². Appropriate degradation rate, bioadhesive nature, mechanical and hydrolytic resistance are the desirable characters imposed by polysaccharide-poly amino acid gels that can be helpful for the successful delivery of drug to its targeted site³³. For example, cross-linking of Inulin with Methacrylic Anhydride and Succinic Anhydride (INU-MA-SA) resulted in the production of a derivative that is reluctant to degradation in the stomach and is compatible to intestinal degradation³⁴. This inulin derivative (INU-MA-SA) has also been tested using Differential Scanning Calorimetry (DSC) for delivery of Non-Steroidal Anti Inflammatory Drugs (NSAIDs). These drugs have the potential to irritate gastric mucosae³⁵. Diflunisal was the NSAID (the drug used to treat early morning angina) used exclusively for this study at pH 4.0 and 7.4. Use of inulin provided defence from the acidic environment in the stomach to the drug and was found to be more useful to avoid any side effects caused as a result of NSAIDs in the stomach. Degradation of inulin occurred in the colon in the presence of the enzyme inulinase²³.

Another study has reported INU-MA-SA hydrogels to be used in conjunction with a β -poly[N-(2-hydroxyethyl)-D, L-aspartamide]. This polysaccharide/poly (amino acid) UV induced hydrogel system was used to deliver protein and peptide-based drugs to the colon. Immunoglobulin G (IgG) was selected as a model drug. These hydrogels were inulinase degradable, compatible with epithelial cells and the

released protein reserved their biological activity.³³ Inulin α - β -polyaspartylhydrazide gels (INUPAH) were made from α - β -polyaspartylhydrazide (PAHy), a synthetic and biocompatible amino acid. The gel was loaded with two therapeutic peptides, glutathione and oxytocin, respectively. The gel was apposite for intestinal delivery of these peptides for the management of inflammatory bowel disease³⁶. Another hydrogel of inulin was obtained by cross-linking inulin derivatives (inulin with divinyl sulfone and succinic anhydride) with trimethylolpropane tris (3-mercaptopropionate). The anti-cancerous drug, 2-Methoxyestradiol was complexed with this hydrogel and found to be apoptotic against Caco-2-cell lines. Also, this gel was reported to be appropriate for colon drug delivery because of its degradation by inulinase and esterase³⁷.

3.2 Solid dispersion

The solid dispersion technology is another method utilised for introducing therapeutics. Here, the therapeutics is dispersed in a hydrophilic matrix³⁸. In this study by Visser, an inulin matrix (Mw: 4kDa) was observed to improve solubility and drug release rates for weakly water-soluble drug TMC240 along with an increase in drug loading threshold (38). Inulin and its derivatives are suitable candidates for solid dispersion drug delivery for a heavy load of lipophilic drugs. Inulin (Mw: 2.3kDa), Inulin derivative Inutec SP1 (inulin backbone with covalently linked lipophilic alkyl side chains), and polyvinylpyrrolidone were spray dried to form a solid dispersion in which the drug was loaded. The drug encapsulation was reported using DSC. All three formulations gave excellent physical stability with Inutec SP1 with utmost dissolution rate owing to its surface-active nature³⁹.

Inulin has also been used as a solid dispersion to give stability to highly unstable, easily degradable and lipophilic Δ 9-tetrahydrocannabinol (THC). A blend of THC and inulin in a solution of water and tertiary butyl alcohol was lyophilised to make a solid dispersion and stored for 7 days at 20°C at 45% relative humidity. This exposure led to total degradation of unprotected THC in 40 days while solid dispersed THC showed only 20% degradation even after 300 days. The high aqueous dissolution rate of the tablets prepared from THC incorporated in inulin matrix was recommended to improve bioavailability in sublingual administration⁴⁰.

In another study based on the stabilizing capability of inulin, it was found that inulin is a better stabiliser than trehalose. The research was targeted to formulate an orally ingestible tablet that can be used to eradicate endotoxins released during sepsis. The compaction behaviour of inulin and trehalose and their effect on the loaded bovine isolated alkaline phosphate (BIAP) was observed. Trehalose tends to crystallize upon compaction and had moisture in it while inulin had low friability, was stable at high relative humidities and offered good tableting strength. Thus, inulin had a benefit over trehalose as a stabiliser of BIAP in the form of a tablet⁴¹.

4. Conclusion

Inulin is versatile polysaccharide that can be used as a drug delivery vehicle, as a diagnostic tool or as a dietary fibre with widespread health benefits. In this review study, the drug targeting potential of inulin has been reviewed. Inulin's chemical structure makes that it is not degraded by the upper gastrointestinal tract. Gut micro-biota, however, are able to metabolize inulin. This unique stability and strength are utilized in a number of ways to deliver drugs safely to the colon where they can be easily absorbed through the gut

epithelium into the blood. There are some proofs that inulin's prebiotic features also lead to health benefits, mainly for patients with inflammatory bowel disease or in the prevention of colonic cancer. Inulin based hydrodynamic research will be valuable to find out inulin potential. In addition, more and more research is being made with chemically tailored inulins, making it likely that more applications will be established for this versatile polysaccharide.

References

1. Yun YH, Lee BK, Park K. Controlled drug delivery: historical perspective for the next generation. *Journal of Controlled Release*. 2015; 219:2-7.
2. Damian F, Van Den Mooter G, Samyn C, Kinget R. In vitro biodegradation study of acetyl and methyl inulins by Bifidobacteria and inulinase. *European journal of pharmaceuticals and biopharmaceuticals*. 1999; 47(3):275-82.
3. Vandamme TF, Lenourry A, Charrueau C, Chaumeil JC. The use of polysaccharides to target drugs to the colon. *Carbohydrate polymers*. 2002; 48(3):219-31.
4. Zhang L, Sang Y, Feng J, Li Z, Zhao A. Polysaccharide-based micro/nanocarriers for oral colon-targeted drug delivery. *Journal of drug targeting*. 2016; 24(7):579-89.
5. López-Molina D, Navarro-Martínez MD, Rojas-Melgarejo F, Hiner AN, Chazarra S, Rodríguez-López JN. Molecular properties and prebiotic effect of inulin obtained from artichoke (*Cynara scolymus* L.). *Phytochemistry*. 2005; 66(12):1476-84.
6. Apolinario AC, de Lima Damasceno BP, de Macedo Beltrao NE, Pessoa A, Converti A, da Silva JA. Inulin-type fructans: A review on different aspects of biochemical and pharmaceutical technology. *Carbohydrate polymers*. 2014; 101:368-78.
7. Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs WL. Inulin, a flexible oligosaccharide. II: Review of its pharmaceutical applications. *Carbohydrate polymers*. 2015; 134:418-28.
8. Petrovsky N. Inulin-a versatile polysaccharide: use as food chemical and pharmaceutical agent. *Journal of Excipients and Food Chemicals*. 2010; 1(3):27-50.
9. Hartzell AL, Maldonado-Gómez MX, Hutkins RW, Rose DJ. Synthesis and in vitro digestion and fermentation of acylated inulin. *Bioactive Carbohydrates and Dietary Fibre*. 2013; 1(1):81-8.
10. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. *Frontiers in microbiology*. 2016; 7:979.
11. Stevens CV, Meriggi A, Booten K. Chemical modification of inulin, a valuable renewable resource, and its industrial applications. *Biomacromolecules*. 2001; 2(1):1-6.
12. Kelly G. Inulin-type prebiotics--a review: part 1. *Alternative Medicine Review*. 2008; 13(4).
13. Jain AK, Sood V, Bora M, Vasita R, Katti DS. Electrospayed inulin microparticles for microbiota triggered targeting of colon. *Carbohydrate polymers*. 2014; 112:225-34.
14. Raninen K, Lappi J, Mykkänen H, Poutanen K. Dietary fiber type reflects physiological functionality: comparison of grain fiber, inulin, and polydextrose. *Nutrition reviews*. 2011; 69(1):9-21.
15. Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs WL. Inulin, a flexible oligosaccharide I: Review of its physicochemical characteristics. *Carbohydrate polymers*. 2015; 130:405-19.
16. Carlson JL, Erickson JM, Hess JM, Gould TJ, Slavin JL. Prebiotic Dietary Fiber and Gut Health: Comparing the in Vitro Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide. *Nutrients*. 2017; 9(12):1361.
17. Smecuol E, Hwang HJ, Sugai E, Corso L, Chernavsky AC, Bellavite FP, Gonzalez A, Vodanovich F, Moreno ML, Vazquez H, Lozano G. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natrene life start strain super strain in active celiac disease. *Journal of clinical gastroenterology*. 2013; 47(2):139-47.
18. López-Molina D, Chazarra S, How CW, Pruidze N, Navarro-Perán E, García-Cánovas F, García-Ruiz PA, Rojas-Melgarejo F, Rodríguez-López JN. Cinnamate of inulin as a vehicle for delivery of colonic drugs. *International journal of pharmaceuticals*. 2015; 479(1):96-102.
19. Goudberg A. The utilization of inulin in the metabolism for nutritional cures. *Z. Exp. Path. Ther.* 1913; 13:310-25.
20. Phelps CF. The physical properties of inulin solutions. *Biochemical Journal*. 1965; 95(1):41.
21. Looijer-Van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. *Inflammatory bowel diseases*. 2008; 15(3):454-62.
22. Flamm G, Glinsmann W, Kritchevsky D, Prosky L, Roberfroid M. Inulin and oligofructose as dietary fiber: a review of the evidence. *Critical reviews in food science and nutrition*. 2001; 41(5):353-62.
23. Castelli F, Sarpietro MG, Micieli D, Ottimo S, Pitarresi G, Tripodo G, Carlisi B, Giammona G. Differential scanning calorimetry study on drug release from an inulin-based hydrogel and its interaction with a biomembrane model: pH and loading effect. *European Journal of Pharmaceutical Sciences*. 2008; 35(1-2):76-85.
24. Akhgari A, Farahmand F, Garekani HA, Sadeghi F, Vandamme TF. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery. *European journal of pharmaceutical sciences*. 2006; 28(4):307-14.
25. Kleberg K, Jacobsen J, Müllertz A. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. *Journal of Pharmacy and Pharmacology*. 2010; 62(11):1656-68.
26. Fares MM, Khanfar M. Inulin and poly (acrylic acid) grafted inulin for dissolution enhancement and preliminary controlled release of poorly water-soluble Irbesartan drug. *International journal of pharmaceuticals*. 2011; 410(1-2):206-11.
27. Dan A, Ghosh S, Moulik SP. Physicochemical studies on the biopolymer inulin: A critical evaluation of its self-aggregation, aggregate-morphology, interaction with water, and thermal stability. *Biopolymers: Original Research on Biomolecules*. 2009; 91(9):687-99.
28. Dan A, Ghosh S, Moulik SP. Physicochemistry of the interaction between inulin and alkyltrimethylammonium bromides in aqueous medium and the formed coacervates. *The Journal of Physical Chemistry B*. 2009; 113(25):8505-13.
29. Naskar B, Ghosh S, Nagadome S, Sugihara G, Moulik SP. Behavior of the amphiphile CHAPS alone and in combination with the biopolymer inulin in water and isopropanol-water media. *Langmuir*. 2011; 27(15):9148-59.
30. Ravi V, Kumar TP. Influence of natural polymer coating on novel colon targeting drug delivery system. *Journal of Materials Science: Materials in Medicine*. 2008; 19(5):2131-6.
31. Lacorn M, Goerke M, Claus R. Inulin-coated butyrate increases ileal MCT1 expression and affects mucosal morphology in the porcine ileum by reduced apoptosis. *Journal of animal physiology and animal nutrition*. 2010; 94(5):670-6.
32. Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. *J Pharm Pharm Sci*. 2007; 10(1):86-128.
33. Tripodo G, Pitarresi G, Cavallaro G, Palumbo FS, Giammona G. Controlled release of IgG by novel UV induced polysaccharide/poly (amino acid) hydrogels. *Macromolecular bioscience*. 2009; 9(4):393-401.
34. Tripodo G, Pitarresi G, Palumbo FS, Craparo EF, Giammona G. UV-photocrosslinking of inulin derivatives to produce hydrogels for drug delivery application. *Macromolecular bioscience*. 2005; 5(11):1074-84.
35. Huang C, Lu B, Fan YH, Zhang L, Jiang N, Zhang S, Meng LN. Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury. *World Journal of Gastroenterology: WJG*. 2014; 20(31):11012.
36. Mandracchia D, Denora N, Franco M, Pitarresi G, Giammona G, Trapani G. New biodegradable hydrogels based on inulin and α , β -polyaspartylhydrazide designed for colonic drug delivery: in vitro release of glutathione and oxytocin. *Journal of Biomaterials Science, Polymer Edition*. 2011; 22(1-3):313-28.
37. Pitarresi G, Tripodo G, Calabrese R, Craparo EF, Licciardi M, Giammona G. Hydrogels for Potential Colon Drug Release by Thiol-ene Conjugate Addition of a New Inulin Derivative. *Macromolecular bioscience*. 2008; 8(10):891-902.
38. Visser MR, Baert L, van't Klooster G, Schueller L, Geldof M, Vanwelkenhuysen I, De Kock H, De Meyer S, Frijlink HW, Rosier

- J, Hinrichs WL. Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. *European Journal of Pharmaceutics and Biopharmaceutics*. 2010; 74(2):233-8.
39. Srinarong P, Hämäläinen S, Visser MR, Hinrichs WL, Ketolainen J, Frijlink HW. Surface-active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug load. *Journal of pharmaceutical sciences*. 2011; 100(6):2333-42.
40. Van Drooge DJ, Hinrichs WL, Wegman KA, Visser MR, Eissens AC, Frijlink HW. Solid dispersions based on inulin for the stabilisation and formulation of Δ^9 -tetrahydrocannabinol. *European journal of pharmaceutical sciences*. 2004; 21(4):511-8.
41. Eriksson HJ, Verweij WR, Poelstra K, Hinrichs WL, de Jong GJ, Somsen GW, Frijlink HW. Investigations into the stabilisation of drugs by sugar glasses: II: Delivery of an inulin-stabilised alkaline phosphatase in the intestinal lumen via the oral route. *International journal of pharmaceutics*. 2003; 257(1-2):273-81.

Journal of Drug Delivery & Therapeutics



JDDT